

Supplement Table S1. Baseline characteristics of patients with *H. pylori* and with and without eradication therapy.

Variable	Proportion among patients with eradication therapy (N, %) N=13,737	Proportion among patients without eradication therapy (N, %) N=11,580	p-value
Age (Mean, SD)	53.4 (15.7)	53.0 (16.0)	0.068
Age 18-30	3,066 (22.3)	2,740 (23.7)	
Age 31-40	2,798 (20.4)	2,317 (20.0)	
Age 41-50	3,188 (23.2)	2,651 (22.9)	0.164
Age 51-60	2,453 (17.9)	2,039 (17.6)	
Age >60	2,232 (16.3)	1,833 (15.8)	
Female	7,940 (57.8)	6,801 (58.7)	0.135
Male	5,797 (42.2)	4,779 (41.3)	
Number of physician visits per year during the follow-up (Mean, SD)	7.6 (3.7)	7.4 (3.8)	0.062
Charlson Comorbidity Score (CCS)	2.0 (1.7)	2.1 (1.8)	0.074
Index year 2005-2008	1,785 (13.0)	1,293 (11.2)	
Index year 2009-2012	2,530 (18.4)	2,253 (19.5)	
Index year 2013-2016	4,393 (32.0)	4,021 (34.7)	<0.001
Index year 2017-2021	5,029 (36.6)	4,013 (34.6)	

Proportions of patients given in N and % unless otherwise indicated. SD: standard deviation.

Supplement Table S2. Cancer incidence (cases per 1000 person-years) in individuals with and without *H. pylori*

Subcohort	Incidence of cancer among patients with <i>H. pylori</i> (cases per 1000 person-years)	Incidence of cancer among patients without <i>H. pylori</i> (cases per 1000 person-years)
Total	13.2	11.7
Age 18-30	2.6	2.6
Age 31-40	7.3	6.2
Age 41-50	12.4	11.8
Age 51-60	20.3	19.0
Age >60	30.5	25.6
Female	12.2	11.0
Male	14.6	12.8